Active, Not Recruiting
BMS-986012 in Relapsed/Refractory SCLC - CA001-030
Actualizada: 30 marzo, 2020 | ClinicalTrials.gov
Imprimir Resumen
Detalles del estudio
Fase
Géneros
Rango de edad
Active, Not Recruiting
Opciones de tratamiento
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histological or cytological confirmed small cell lung cancer (SCLC) - Performance Status 0-1 - Adequate organ function - Measurable disease Exclusion Criteria: - Known or suspected brain metastasis - Small cell cancer not lung in origin - Significant or acute medical illness - Uncontrolled or significant cardiac disease - Infection - ≥ Grade 2 peripheral neuropathy - Concomitant malignancies - HIV related disease or known or suspected HIV+ - Hepatitis B or C infection - ECG abnormalities as defined by the protocol - Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related compounds, including fucosyl-GM1 vaccine and Nivolumab Other protocol defined inclusion/exclusion criteria could apply
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
